Zurück zu Projekte

15235.1 PFLS-LS

HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci

Zusammenfassung

HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci

Weitere Texte

Abstract

A new and highly innovative treatment will be realized by a novel and patentable small molecule|combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic|staphylococci. The consortium integrates a screening platform, biophysical characterization of small|molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models,|to develop initial HIT compounds into preclinical candidates

Beteiligte

Marc Gitzinger

Wirtschaftspartner

BioVersys AG Marc Gitzinger Hochbergerstrasse 60c 4057 Basel BS CH

Rainer Riedl

Kontaktperson

rainer.riedl@zhaw.ch

ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-07-31
Enddatum
2015-07-31
Bewilligte Gesamtkosten
CHF 971582.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%